- Home
- SAVA vs NMT Comparison
SAVA vs NMT Comparison
Compare SAVA & NMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- NMT
- Stock Information
- Founded
- SAVA 1998
- NMT 1993
- Country
- SAVA United States
- NMT United States
- Employees
- SAVA N/A
- NMT N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- NMT Finance/Investors Services
- Sector
- SAVA Health Care
- NMT Finance
- Exchange
- SAVA Nasdaq
- NMT Nasdaq
- Market Cap
- SAVA 102.4M
- NMT 105.7M
- IPO Year
- SAVA N/A
- NMT N/A
- Fundamental
- Price
- SAVA $2.16
- NMT $11.53
- Analyst Decision
- SAVA Hold
- NMT
- Analyst Count
- SAVA 1
- NMT 0
- Target Price
- SAVA $2.00
- NMT N/A
- AVG Volume (30 Days)
- SAVA 607.2K
- NMT 19.1K
- Earning Date
- SAVA 11-06-2025
- NMT 01-01-0001
- Dividend Yield
- SAVA N/A
- NMT 3.21%
- EPS Growth
- SAVA N/A
- NMT N/A
- EPS
- SAVA N/A
- NMT N/A
- Revenue
- SAVA N/A
- NMT N/A
- Revenue This Year
- SAVA N/A
- NMT N/A
- Revenue Next Year
- SAVA N/A
- NMT N/A
- P/E Ratio
- SAVA N/A
- NMT N/A
- Revenue Growth
- SAVA N/A
- NMT N/A
- 52 Week Low
- SAVA $1.15
- NMT $9.05
- 52 Week High
- SAVA $33.98
- NMT $10.93
- Technical
- Relative Strength Index (RSI)
- SAVA 45.76
- NMT 60.23
- Support Level
- SAVA $2.12
- NMT $11.14
- Resistance Level
- SAVA $2.40
- NMT $11.58
- Average True Range (ATR)
- SAVA 0.10
- NMT 0.12
- MACD
- SAVA -0.01
- NMT 0.05
- Stochastic Oscillator
- SAVA 17.24
- NMT 88.89
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.